Clinical trial
A Pre-Market, First-In-Human, Pilot, Interventional, Clinical Investigation to Evaluate the Safety of the Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS) in Premenopausal Women With Abnormal Uterine Bleeding (AUB).
NCT07580560 is registered in ClinicalTrials.gov with Aqua Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pre-Market, First-In-Human, Pilot, Interventional, Clinical Investigation to Evaluate the Safety of the Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS) in Premenopausal Women With Abnormal Uterine Bleeding (AUB).
- Lead sponsor
- Aqua Therapeutics, Inc.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- November 28, 2024
- Completion date
- December 1, 2025
- Enrollment
- 10 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.